Observational Study to Observe the Safety of Levemir® Treatment in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This observational study is conducted in Europe. The study aims to observe the incidence of serious adverse drug reactions in subjects with type 2 diabetes during Levemir® treatment.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Detemir

Criteria

Inclusion Criteria:

• Any patient with type 2 diabetes

• Currently treated with basal human insulin therapy (basal only or in combination with oral glucose lowering drugs or other insulin)

• Selection of patients will be at the discretion of the treating physician after the decision to prescribe one of the study products to the patient

Exclusion Criteria:

• Known or suspected allergy to study product(s) or related products.

• Pregnancy or breastfeeding or intention of becoming pregnant within the next 6 months